Generic Weight-Loss Drug Semaglutide Coming Soon

The active ingredient, semaglutide, is the powerhouse behind Novo Nordisk's blockbuster drugs Ozempic and Wegovy. These medications propelled the Danish pharmaceutical company's market value to become one of the largest in the world, with combined sales reaching tens of billions of dollars annually. Originally developed to treat type 2 diabetes, semaglutide was first approved by the FDA in 2017 under the brand name Ozempic. During clinical trials, significant weight loss was observed as a side effect, which led to further studies and its eventual approval at a higher dose for weight management under the name Wegovy in 2021. The list price for a one-month supply of brand-name Wegovy is approximately $1,349 in the United States, while Ozempic's list price is around $998, creating a significant cost barrier for patients without insurance coverage. These high prices have fueled intense demand for more affordable generic alternatives. The arrival of generics is staggered globally due to a complex web of patents. While key patents in the U.S. and Europe are not expected to expire until the early 2030s, the patent protection in countries like Canada, China, and India is ending as early as 2026. Major generic drug manufacturers like Sandoz, Viatris, and Teva are among the companies preparing to enter the market. Sandoz has already submitted its generic for approval in Canada, aiming for a 2026 launch, while numerous firms in India and China are also gearing up for production. The introduction of generics is expected to dramatically reduce costs. In Canada, one generic manufacturer projected a potential price reduction of 60% to 70%, which could bring the monthly cost down from around $400 to under $100. In India, analysts predict costs could eventually fall to as low as $40 a month. This shift is part of a larger trend in the booming market for GLP-1 drugs, which includes competitors like Eli Lilly's Zepbound. The entry of the first generic GLP-1 for weight loss, a version of the older drug liraglutide (Saxenda) by Teva, has already signaled the beginning of increased competition in the weight-management medication space.